Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Pegram

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Breast Cancer Research and Treatment|May 5, 2018
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)Jame Abraham, Robert Coleman, Anthony Elias, et al.
Cancer Gene Therapy|June 26, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller, Mark S Shahin, Jo Ann Horowitz, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced SenescenceZhiming Wang, Yuanhui Liu, Hala S Hassanain, et al.
The Lancet. Oncology|May 21, 2017
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trialVéronique Diéras, David Miles, Sunil Verma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapyClare Taylor, Dawn Hershman, Nina Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast CancerHope S Rugo, Virginia Kaklamani, Heather McArthur, et al.
NPJ Breast Cancer|October 9, 2021
A careful reassessment of anthracycline use in curable breast cancerSara Alsterlind Hurvitz, Nicholas P McAndrew, Aditya Bardia, et al.
Breast Cancer Research and Treatment|January 21, 2018
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)Jame Abraham, Humberto Caldera, Robert Coleman, et al.
Clinical Breast Cancer|March 7, 2020
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast CancerReshma Mahtani, Frankie-Ann Holmes, Sunil Badve, et al.
The New England Journal of Medicine|October 2, 2012
Trastuzumab emtansine for HER2-positive advanced breast cancerSunil Verma, David Miles, Luca Gianni, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Breast Cancer Research and Treatment|May 5, 2018
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)Jame Abraham, Robert Coleman, Anthony Elias, et al.
Cancer Gene Therapy|June 26, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller, Mark S Shahin, Jo Ann Horowitz, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced SenescenceZhiming Wang, Yuanhui Liu, Hala S Hassanain, et al.
The Lancet. Oncology|May 21, 2017
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trialVéronique Diéras, David Miles, Sunil Verma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapyClare Taylor, Dawn Hershman, Nina Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast CancerHope S Rugo, Virginia Kaklamani, Heather McArthur, et al.
NPJ Breast Cancer|October 9, 2021
A careful reassessment of anthracycline use in curable breast cancerSara Alsterlind Hurvitz, Nicholas P McAndrew, Aditya Bardia, et al.
Breast Cancer Research and Treatment|January 21, 2018
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)Jame Abraham, Humberto Caldera, Robert Coleman, et al.
Clinical Breast Cancer|March 7, 2020
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast CancerReshma Mahtani, Frankie-Ann Holmes, Sunil Badve, et al.
The New England Journal of Medicine|October 2, 2012
Trastuzumab emtansine for HER2-positive advanced breast cancerSunil Verma, David Miles, Luca Gianni, et al.
Pageof 7